Bioline Rx (BLRX) and Gamida Cell (GMDA)’s parent company, Ayrmid, the parent company of BioLineRx’s FDA-approved stem cell mobilization agent, is indicated for use in combination with filgrastim for collection and subsequent autologous transplantation in patients with multiple myeloma. The two companies announced that they have entered into a licensing agreement for motixafortide. . Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda in all indications except solid tumor indications and in all regions except Asia. BioLineRx previously granted an exclusive license agreement for Aphexda in Asia to Gloria Biosciences. In exchange for the license, BioLineRx will receive an upfront payment of $10 million and is also eligible to receive potential commercial milestones of up to $87 million and royalties of 18% to 23% on Aphexda’s net sales. Ayrmid plans to add Aphexda to its commercial portfolio, which also includes Gamida Cell’s Omisirge, the first and only FDA-approved nicotinamide- or NAM-modified cell therapy for patients with hematologic malignancies requiring stem cell transplants. It will be done. As part of the transaction, Airmid will transfer certain members of BioLineRx’s U.S.-based commercial organization that supports both stem cell transplant medicines. Through this transaction, BioLineRx will significantly reduce its long-term debt and operating expenses. This will be discussed in detail during the company’s upcoming third quarter earnings conference call and webcast. BioLineRx also entered into a stock purchase agreement for a $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC. This investment, together with potential future commercial milestones and royalties on net sales from the license agreements with Ayrmid and Gloria Biosciences, will help BioLineRx advance its pipeline and increase the potential for development. It is expected to provide a strong basis for identifying additional assets. This equity investment is expected to close today, November 21, subject to the satisfaction of customary closing conditions. BioLineRx is committed to improving the pancreatic duct through meaningful collaborations, including an active Phase 2b PDAC study led by Columbia University and supported equally by BioLineRx and Regeneron, and a planned Phase 2b PDAC study in China led by Gloria Biosciences. We will continue to develop motixafortide for adenocarcinoma. .
